TROP2抗体の世界市場 - 臨床試験の考察：2026年
Global TROP2 Antibody Market & Clinical Trials Insight 2026
|TROP2抗体の世界市場 - 臨床試験の考察：2026年|
発行: KuicK Research
ページ情報: 英文 90 Pages
TROP2 (Trophoblast surface antigen 2) は、上皮細胞の膜表面に存在する細胞表面タンパク質で、細胞の自己再生、増殖、形質転換に関与しています。TROP2は、正常な生理条件下では、胚の発生、胎盤組織の形成、胚の着床、幹細胞の増殖、臓器の発生などに関与していることが明らかになっています。さらに、TROP2はいくつかのがん細胞に高度に発現しており、一般的にがん細胞の攻撃性と関連していることも明らかになっています。また、TROP2は、がん細胞の成長や増殖につながるいくつかのシグナル伝達経路にも関与しています。したがって、TROP2を標的とすることは、がんを標的とするための代替手段になる可能性があります。
“Global TROP2 Antibody Market & Clinical Trials Insight 2026” Report Analysis and Data Highlights:
Trophoblast surface antigen 2 (Trop2) is a cell surface protein which spans the epithelial membrane surface and plays role in cell self-renewal, proliferation, and transformation. Under normal physiological conditions, Trop2 has demonstrated its role in embryonic development, placental tissue formation, embryo implantation, stem cell proliferation, and organ development. Further, studies have also demonstrated that Trop2 is highly expressed on several cancer cells and is generally associated with its aggressive nature. Apart from this, it is also involved in several signaling pathways which ultimately lead to cancer cell growth and proliferation. Therefore, targeting Trop2 can be an alternative to target cancer.
Recently, scientists developed novel antibody drug conjugate in which the therapeutic antibody is targeted towards Trop2, thereby delivering the cytotoxin to the surface of tumor cell. Sacituzumab govitecan-hziy (Trodelvy) developed by Immunomedics is the first trop2 targeted antibody drug conjugate which has been approved for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The introduction of Trodelvy in 2020 is expected to witness high growth rates in market due to lack of effective targeted therapies in mTNBC. It is believed that Trodelvy will revolutionize the overall treatment of TNBC and will significantly improve the survival outcomes.
Beyond the approval of Trodelvy in US, it has also gained approval in Australia, Canada, UK, and Switzerland for adults with metastatic TNBC. Apart from this, the drug is present in regulatory view in other regions including Europe, China and Singapore. Recently, European Medicines Agency has recommended the marketing of Trodelvy, indicating that the drug will enter the market in coming months. The rapid approval of drug in different regions will fuel the growth of market in coming years.
The quick approval of Trodelvy has further empowered innovation and development in this sector. To date, a cocktail of Trop2 targeted drugs including DS-1062a, RN927C, BAT8003, SKB264, JS108 are present in clinical development. These drugs have been designed to target a wide range of cancer including non-small cell lung cancer, epithelial cancer, skin cancer, colon cancer, and others. Apart from this, several investigational studies are also ongoing to evaluate the efficacy of Trodelvy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway. The forthcoming years will see rapid influx of Trop-2 targeted therapies in wide range of cancers.
The key players in the TROP2 Antibody market include Daiichi Sankyo, Immunomedics, Gilead Sciences, AstraZeneca, Pfizer, BioThera Solution, and others. The major players in the market have adopted strategic alliances such as collaboration, partnerships, or joint ventures to cope up with the high cost of research and development and to maintain their share in market. For instance, Daiichi Sankyo and AstraZeneca have recently announced second trial collaboration with Merck to evaluate the combination of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) and Keytruda in non-small cell lung cancer patients.
The global Trop2 targeting drug market is expected to surpass US$ 4 Billion by 2026. Surge in prevalence of cancer across geographies, high demand for targeted therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers and insurance providers, and rise in awareness of Trop-2 targeting drug owing o high efficiency will propel the growth of market. In addition, surge in geriatric population and increase in technological advancements in screening & diagnosis of cancer supplement the market growth.